clinical trial · NCT05324293
To Evaluate the Safety, Tolerability and Efficacy in Male and Female with AGA Treated with HMI-115 Over a 24-week Treatment Period
Hope Medicine (Nanjing) Co., Ltd·phase1·completed·n = 16
Androgenetic AlopeciaHMI-115
brief summary
An Open Label Study, to Evaluate Safety, Tolerability, and Efficacy Study in Male and Female with Androgenetic Alopecia Treated with HMI-115 over a 24-Week Treatment Period.
started
May 11, 2022
primary completion
Sep 11, 2023
completion
Sep 11, 2023
last updated
Sep 19, 2024
official title
An Open Label Study, to Evaluate Safety, Tolerability, and Efficacy in Male and Female with Androgenetic Alopecia Treated with HMI-115 Over a 24-Week Treatment Period
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol